These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 33541085)

  • 1. Discovery of Novel
    Li R; Ling D; Tang T; Huang Z; Wang M; Ding Y; Liu T; Wei H; Xu W; Mao F; Zhu J; Li X; Jiang L; Li J
    J Med Chem; 2021 Feb; 64(4):2254-2271. PubMed ID: 33541085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug Repurposing of Quisinostat to Discover Novel
    Wang M; Tang T; Li R; Huang Z; Ling D; Zheng L; Ding Y; Liu T; Xu W; Zhu F; Min H; Boonhok R; Mao F; Zhu J; Li X; Jiang L; Li J
    J Med Chem; 2022 Mar; 65(5):4156-4181. PubMed ID: 35175762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Procainamide-SAHA Fused Inhibitors of hHDAC6 Tackle Multidrug-Resistant Malaria Parasites.
    Nardella F; Halby L; Dobrescu I; Viluma J; Bon C; Claes A; Cadet-Daniel V; Tafit A; Roesch C; Hammam E; Erdmann D; Mairet-Khedim M; Peronet R; Mecheri S; Witkowski B; Scherf A; Arimondo PB
    J Med Chem; 2021 Jul; 64(14):10403-10417. PubMed ID: 34185525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repurposing Anticancer Drugs To Tackle Malaria.
    Le Govic Y; Houzé S; Papon N
    ChemMedChem; 2021 Jul; 16(14):2192-2194. PubMed ID: 33931947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimalarial activity of phenylthiazolyl-bearing hydroxamate-based histone deacetylase inhibitors.
    Dow GS; Chen Y; Andrews KT; Caridha D; Gerena L; Gettayacamin M; Johnson J; Li Q; Melendez V; Obaldia N; Tran TN; Kozikowski AP
    Antimicrob Agents Chemother; 2008 Oct; 52(10):3467-77. PubMed ID: 18644969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure activity refinement of phenylsulfonyl piperazines as antimalarials that block erythrocytic invasion.
    Nguyen W; Dans MG; Ngo A; Gancheva MR; Romeo O; Duffy S; de Koning-Ward TF; Lowes KN; Sabroux HJ; Avery VM; Wilson DW; Gilson PR; Sleebs BE
    Eur J Med Chem; 2021 Mar; 214():113253. PubMed ID: 33610028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and Synthesis of Terephthalic Acid-Based Histone Deacetylase Inhibitors with Dual-Stage Anti-Plasmodium Activity.
    Stenzel K; Chua MJ; Duffy S; Antonova-Koch Y; Meister S; Hamacher A; Kassack MU; Winzeler E; Avery VM; Kurz T; Andrews KT; Hansen FK
    ChemMedChem; 2017 Oct; 12(19):1627-1636. PubMed ID: 28812327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of Clinical Pharmacology in Chemotherapy of Multidrug-Resistant Plasmodium falciparum.
    Karbwang J; Na-Bangchang K
    J Clin Pharmacol; 2020 Jul; 60(7):830-847. PubMed ID: 32108367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lead Optimization of a Pyrrole-Based Dihydroorotate Dehydrogenase Inhibitor Series for the Treatment of Malaria.
    Kokkonda S; Deng X; White KL; El Mazouni F; White J; Shackleford DM; Katneni K; Chiu FCK; Barker H; McLaren J; Crighton E; Chen G; Angulo-Barturen I; Jimenez-Diaz MB; Ferrer S; Huertas-Valentin L; Martinez-Martinez MS; Lafuente-Monasterio MJ; Chittimalla R; Shahi SP; Wittlin S; Waterson D; Burrows JN; Matthews D; Tomchick D; Rathod PK; Palmer MJ; Charman SA; Phillips MA
    J Med Chem; 2020 May; 63(9):4929-4956. PubMed ID: 32248693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of a potent histone deacetylase (HDAC) 3/6 selective dual inhibitor.
    Soumyanarayanan U; Ramanujulu PM; Mustafa N; Haider S; Fang Nee AH; Tong JX; Tan KSW; Chng WJ; Dymock BW
    Eur J Med Chem; 2019 Dec; 184():111755. PubMed ID: 31627059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of spiropiperidine hydantoins as a novel class of antimalarial agents.
    Meyers MJ; Anderson EJ; McNitt SA; Krenning TM; Singh M; Xu J; Zeng W; Qin L; Xu W; Zhao S; Qin L; Eickhoff CS; Oliva J; Campbell MA; Arnett SD; Prinsen MJ; Griggs DW; Ruminski PG; Goldberg DE; Ding K; Liu X; Tu Z; Tortorella MD; Sverdrup FM; Chen X
    Bioorg Med Chem; 2015 Aug; 23(16):5144-50. PubMed ID: 25797165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two-pronged attack: dual inhibition of Plasmodium falciparum M1 and M17 metalloaminopeptidases by a novel series of hydroxamic acid-based inhibitors.
    Mistry SN; Drinkwater N; Ruggeri C; Sivaraman KK; Loganathan S; Fletcher S; Drag M; Paiardini A; Avery VM; Scammells PJ; McGowan S
    J Med Chem; 2014 Nov; 57(21):9168-83. PubMed ID: 25299353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of 1,2,4-oxadiazole-Containing hydroxamic acid derivatives as histone deacetylase inhibitors potential application in cancer therapy.
    Yang Z; Shen M; Tang M; Zhang W; Cui X; Zhang Z; Pei H; Li Y; Hu M; Bai P; Chen L
    Eur J Med Chem; 2019 Sep; 178():116-130. PubMed ID: 31177073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum.
    Chen Y; Lopez-Sanchez M; Savoy DN; Billadeau DD; Dow GS; Kozikowski AP
    J Med Chem; 2008 Jun; 51(12):3437-48. PubMed ID: 18494463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydroxamic acid based histone deacetylase inhibitors with confirmed activity against the malaria parasite.
    Giannini G; Battistuzzi G; Vignola D
    Bioorg Med Chem Lett; 2015 Feb; 25(3):459-61. PubMed ID: 25563890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of HDAC inhibitors with potent activity against multiple malaria parasite life cycle stages.
    Hansen FK; Sumanadasa SD; Stenzel K; Duffy S; Meister S; Marek L; Schmetter R; Kuna K; Hamacher A; Mordmüller B; Kassack MU; Winzeler EA; Avery VM; Andrews KT; Kurz T
    Eur J Med Chem; 2014 Jul; 82():204-13. PubMed ID: 24904967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of FNDR-20123, a histone deacetylase inhibitor for the treatment of Plasmodium falciparum malaria.
    Potluri V; Shandil RK; Gavara R; Sambasivam G; Campo B; Wittlin S; Narayanan S
    Malar J; 2020 Oct; 19(1):365. PubMed ID: 33046062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone methyltransferase inhibitors are orally bioavailable, fast-acting molecules with activity against different species causing malaria in humans.
    Malmquist NA; Sundriyal S; Caron J; Chen P; Witkowski B; Menard D; Suwanarusk R; Renia L; Nosten F; Jiménez-Díaz MB; Angulo-Barturen I; Santos Martínez M; Ferrer S; Sanz LM; Gamo FJ; Wittlin S; Duffy S; Avery VM; Ruecker A; Delves MJ; Sinden RE; Fuchter MJ; Scherf A
    Antimicrob Agents Chemother; 2015 Feb; 59(2):950-9. PubMed ID: 25421480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lead Optimization of Dehydroemetine for Repositioned Use in Malaria.
    Panwar P; Burusco KK; Abubaker M; Matthews H; Gutnov A; Fernández-Álvaro E; Bryce RA; Wilkinson J; Nirmalan N
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31964796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimalarial activity of the anticancer histone deacetylase inhibitor SB939.
    Sumanadasa SD; Goodman CD; Lucke AJ; Skinner-Adams T; Sahama I; Haque A; Do TA; McFadden GI; Fairlie DP; Andrews KT
    Antimicrob Agents Chemother; 2012 Jul; 56(7):3849-56. PubMed ID: 22508312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.